Despite their potential, nanovaccines face several challenges. The safety and biocompatibility of the nanoparticles must be thoroughly evaluated. There is also a need for scalable and cost-effective manufacturing processes. Regulatory pathways for nanovaccines are still evolving, which can delay their approval and widespread use.
